ES2113865T3 - Gen pnc humano y proteina precursora. - Google Patents

Gen pnc humano y proteina precursora.

Info

Publication number
ES2113865T3
ES2113865T3 ES91116557T ES91116557T ES2113865T3 ES 2113865 T3 ES2113865 T3 ES 2113865T3 ES 91116557 T ES91116557 T ES 91116557T ES 91116557 T ES91116557 T ES 91116557T ES 2113865 T3 ES2113865 T3 ES 2113865T3
Authority
ES
Spain
Prior art keywords
human
pnc
gen
precursor protein
cnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91116557T
Other languages
English (en)
Inventor
Shoji Tanaka
Kayoko Fuchimura
Yasunori Tawaragi
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2113865T3 publication Critical patent/ES2113865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL GEN DE UN CNP HUMANO (PEPTIDO NATRIURETICO DE TIPO C HUMANO), ASI COMO LA PROTEINA PRECURSORA DE HCNP QUE ESTA CODIFICADA POR ESTE GEN. EL PRECURSOR DE HCNP ESTA REPRESENTADO POR LA SIGUIENTE SECUENCIA DE AMINOACIDO. EL PRECURSOR DE HCNP Y SUS DERIVADOS SON NUEVOS Y TIENEN ACTIVIDADES NATRIURETICAS E HIPOTENSORAS.
ES91116557T 1990-09-27 1991-09-27 Gen pnc humano y proteina precursora. Expired - Lifetime ES2113865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトｃｎｐ遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
ES2113865T3 true ES2113865T3 (es) 1998-05-16

Family

ID=17337688

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96114549T Expired - Lifetime ES2302333T3 (es) 1990-09-27 1991-09-27 Gen de un cnp humano y proteina precursora.
ES91116557T Expired - Lifetime ES2113865T3 (es) 1990-09-27 1991-09-27 Gen pnc humano y proteina precursora.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES96114549T Expired - Lifetime ES2302333T3 (es) 1990-09-27 1991-09-27 Gen de un cnp humano y proteina precursora.

Country Status (8)

Country Link
US (1) US6034231A (es)
EP (2) EP0769554B1 (es)
JP (1) JP3026354B2 (es)
AT (2) ATE388165T1 (es)
DE (2) DE69128754T2 (es)
DK (1) DK0477971T3 (es)
ES (2) ES2302333T3 (es)
GR (1) GR3026554T3 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2007061715A2 (en) * 2005-11-18 2007-05-31 The Brigham & Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective vascular endothelium
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
KR101350251B1 (ko) * 2008-05-23 2014-01-14 다이이찌 산쿄 가부시키가이샤 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드
PT2432489T (pt) 2009-05-20 2016-12-07 Biomarin Pharm Inc Variantes do péptido natriurético de tipo c
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
US20230192799A1 (en) 2019-09-16 2023-06-22 Biomarin Pharmaceutical Inc. CNP Variants and Conjugates Thereof
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
EP4444341A1 (en) 2021-12-07 2024-10-16 BioMarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
CN121889516A (zh) 2023-06-07 2026-04-17 生物马林药物股份有限公司 用于与身材矮小相关的遗传变体的高通量筛选
TW202535449A (zh) 2023-11-08 2025-09-16 美商拜奧馬林製藥公司 Ｃｎｐ變異體、其接合物及調配物
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DE69133593T2 (de) 2009-04-02
EP0769554B1 (en) 2008-03-05
EP0477971B1 (en) 1998-01-21
JP3026354B2 (ja) 2000-03-27
US6034231A (en) 2000-03-07
EP0477971A3 (en) 1992-09-09
EP0769554A2 (en) 1997-04-23
ES2302333T3 (es) 2008-07-01
DK0477971T3 (da) 1998-09-21
EP0477971A2 (en) 1992-04-01
ATE388165T1 (de) 2008-03-15
ATE162532T1 (de) 1998-02-15
GR3026554T3 (en) 1998-07-31
DE69128754T2 (de) 1998-06-04
DE69133593D1 (de) 2008-04-17
JPH04139199A (ja) 1992-05-13
EP0769554A3 (en) 1997-05-28
DE69128754D1 (de) 1998-02-26

Similar Documents

Publication Publication Date Title
ES2113865T3 (es) Gen pnc humano y proteina precursora.
IL131016A0 (en) Selection of proteins using rna-protein fusions
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
ES2184728T3 (es) Proteinas de union a la fibronectina.
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
HU906270D0 (en) Anticoagulant peptides
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
ZA899247B (en) Anticoagulant peptides
DK0477217T3 (da) Stabiliserede, potente GRF-analoge
FI900075L (fi) Medvaexthormon bindande peptid.
ES2142840T3 (es) Proteina que se une al interferon alfa/beta, su preparacion y las composiciones farmaceuticas que la contienen.
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
FI944997L (fi) Parannettu rekombinantti-proteiinien tuotanto
NO177858C (no) Peptid
DE3780388D1 (de) Fsh-stimulierendes peptid.
DE3869939D1 (de) Biologisch wirksame peptide.
ATE231887T1 (de) Protein mit anti-tumorwirkung
ITRM920517A1 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
DK369888A (da) Peptidforbindelser
ATE95238T1 (de) Leader-anteile zur produktion von rekombinanten proteinen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 477971

Country of ref document: ES